Get the Stockscreener App
153.29
1.73%
2.61
After Hours:
153.29
Neurocrine Biosciences Inc stock is traded at $153.29, with a volume of 834.63K.
It is up +1.73% in the last 24 hours and up +11.84% over the past month.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$150.68
Open:
$152
24h Volume:
834.63K
Relative Volume:
0.85
Market Cap:
$15.52B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
41.10
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
+3.87%
1M Performance:
+11.84%
6M Performance:
+8.58%
1Y Performance:
+7.91%
1-Day Range:
$151.14
$154.61
1-Week Range:
$145.97
$154.61
52-Week Range:
$110.95
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.52B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
172.71 | 77.92B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.70 | 43.43B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.27B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.84 | 20.21B | 16.77B | -959.00M | 1.37B | -0.85 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 146,105 Shares of Stock - MarketBeat
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results - Victoria Advocate
Neurocrine Biosciences director sells shares worth $21.8 million - MSN
Neurocrine Biosciences director sells shares worth $21.8 million By Investing.com - Investing.com Australia
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - Investing.com
Prentiss Smith & Co. Inc. Invests $650,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal - MSN
Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder - Marketscreener.com
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights - Benzinga
Neurocrine revamps osavampator deal with Takeda - The Pharma Letter
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal By Investing.com - Investing.com Nigeria
Game-Changing Depression Drug Enters Final Testing PhaseCould Help Millions Where Others Failed - StockTitan
Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences - MarketWatch
Neurocrine Amends Collaboration with Takeda on Osavampator -January 27, 2025 at 05:30 pm EST - Marketscreener.com
Neurocrine Biosciences Announces to Develop and Commercialize Osavampator -January 27, 2025 at 04:05 pm EST - Marketscreener.com
Where are the Opportunities in (NBIX) - Stock Traders Daily
Wedbush Forecasts Weaker Earnings for Neurocrine Biosciences - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Increased by Harel Insurance Investments & Financial Services Ltd. - MarketBeat
Daymark Wealth Partners LLC Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - MarketBeat
Andrew Ratz, Ph.D., Appointed Senior Vice President of Drug Development at Neurocrine Biosciences - citybiz
Neurocrine appoints Andrew Ratz as senior VP - The Pharma Letter
Neurocrine Biosciences Appoints SVP of Drug Development, Delivery and Device - Contract Pharma
2,735 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by HB Wealth Management LLC - MarketBeat
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device - Financial Times
Dyskinesia Pipeline 2024: Latest FDA Approvals, Clinical - openPR
Whalen Wealth Management Inc. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine backs CAH-focused supplement in JCEM - MSN
Neurocrine backs CAH-focused supplement in JCEM By Investing.com - Investing.com Australia
Brokers Set Expectations for NBIX FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Reduces Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Neurocrine's CRENESSITY Breakthrough Featured in Major Endocrinology Journal Special Issue - StockTitan
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN
Neurocrine Bio stock retains outperform rating on robust pipeline - MSN
Avanza Fonder AB Invests $1.80 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Kyle Gano Sells 65,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 08 - Marketscreener.com
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock By Investing.com - Investing.com UK
How To Trade (NBIX) - Stock Traders Daily
Endometriosis Pipeline 2024: Detailed Clinical Trials - openPR
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co. - MarketBeat
Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $164.81 Consensus PT from Brokerages - MarketBeat
40 Under 40: Ashley Allan, Neurocrine Biosciences - MM+M Online
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewswire
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - The Manila Times
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences explores new CAH treatments By Investing.com - Investing.com Canada
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):